Posted on May 16, 2013 by Sitemaster
The “New” Prostate Cancer InfoLink apologizes for a delay in letting readers know that on Wednesday the US Food & Drug Administration approved radium-223 dichloride (Xofigo®) for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases, but no known visceral (i.e., soft tissue) metastases. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: castration-resistant, mCRPC, metastatic, radium-223, Xofigo | Leave a Comment »
Posted on May 14, 2013 by Sitemaster
The next prostate cancer Cure Panel Talk Show will be hosting Mark Rubin, MD of Weill Cornell Medical College on May 31 at 4:00 pm EST. The show will be co-hosted by Dan Zenka of the Prostate Cancer Foundation. … READ MORE …
Filed under: Uncategorized | Leave a Comment »
Posted on May 13, 2013 by Sitemaster
A new paper recently published on line in Urology (“the Gold Journal”) suggests that men with diabetes who are treated with curative intent for localized prostate cancer using external beam radiation therapy may experience higher than normal risk for late genitourinary complications and adverse effects. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: diabetes, external beam, localized, radiation | Leave a Comment »
Posted on May 10, 2013 by Sitemaster
Last September we asked whether the Oncotype DX test for risk of prostate cancer developed by Genomic Health was “ready for prime time”. In a media release issued earlier this week, the company said that it was. However, there are a number of unresolved issues that are likely to impact the uptake of this new test. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Uncategorized | Tagged: DX, Oncotype, risk, significant | 4 Comments »
Posted on May 8, 2013 by Sitemaster
Final data have just been reported on the results of a Phase I/II study of treatment with ipilimumab as monotherapy and in combination with radiotherapy in men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE ..
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, ipilimumab, mCRPC, metastatic | Leave a Comment »
Posted on May 8, 2013 by Sitemaster
So the American Urology Association (AUA) is clearly “on a roll” when it comes to guidance on the detection and management of prostate cancer. This is the third new guidance document issued in a matter of days. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: adjuvant, guideline, radiation therapy, radical prostatectomy, salvage | 4 Comments »
Posted on May 6, 2013 by Sitemaster
Earlier today, the American Urological Association issued new guidance to its members on the management of patients with non-metastatic and metastatic castration-resistant prostate cancer (CRPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, CRPC, drug, metastatic, non-metastatic, sequencing, therapy | 1 Comment »
Search for new and
ongoing trials on the
CTAG PCa web site
